Literature DB >> 14528285

Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents.

Brian J Nickoloff1, Barbara A Osborne, Lucio Miele.   

Abstract

Notch signaling controls cell fate decisions including during development and stem cell renewal and differentiation in many postnatal tissues. Increasing evidence suggests that the Notch signaling network is frequently deregulated in human malignancies and that genetic or pharmacological manipulation of Notch signaling is a novel potential strategy for the treatment of human neoplasms. This review article summarizes the most recent preclinical and clinical evidence linking Notch signaling to cancer, delineates questions that remain unanswered and explores potential biopharmacological strategies to manipulate Notch signaling in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528285     DOI: 10.1038/sj.onc.1206758

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  101 in total

Review 1.  Breast cancer stem cell hypothesis: clinical relevance (answering breast cancer clinical features).

Authors:  Nuria Rodríguez Salas; Enrique González González; Carlos Gamallo Amat
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  ErbB2 induces Notch1 activity and function in breast cancer cells.

Authors:  Jaime Lindsay; Xuanmao Jiao; Toshiyuki Sakamaki; Mathew C Casimiro; Lawrence A Shirley; Thai H Tran; Xiaoming Ju; Manran Liu; Zhiping Li; Chenguang Wang; Sanjay Katiyar; Mahadev Rao; Kathleen G Allen; Robert I Glazer; Changhui Ge; Pamela Stanley; Michael P Lisanti; Hallgeir Rui; Richard G Pestell
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 3.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Targeted Therapy of Breast Cancer - New Insights and Perspectives.

Authors:  Joachim Bischoff
Journal:  Breast Care (Basel)       Date:  2008-12-05       Impact factor: 2.860

5.  Elongin C is a mediator of Notch4 activity in human renal tubule cells.

Authors:  Timothy D Cummins; Michael D Mendenhall; Michelle N Lowry; Erik A Korte; Michelle T Barati; Syed J Khundmiri; Sarah A Salyer; Jon B Klein; David W Powell
Journal:  Biochim Biophys Acta       Date:  2011-10-05

6.  EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli.

Authors:  Jae Myun Lee; Kyoung-Ho Lee; Christopher J Farrell; Paul D Ling; Bettina Kempkes; Jeon Han Park; S Diane Hayward
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways.

Authors:  Javier Margareto; Olatz Leis; Eider Larrarte; Miguel A Idoate; Alejandro Carrasco; José Vicente Lafuente
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

8.  Functional redundancy of the Notch pathway in ovarian cancer cell lines.

Authors:  Fernanda Silva; Ana Félix; Jacinta Serpa
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

Review 9.  Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Authors:  Ie-Ming Shih; Ben Davidson
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

10.  NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.

Authors:  Xing Fan; Leila Khaki; Thant S Zhu; Mary E Soules; Caroline E Talsma; Naheed Gul; Cheryl Koh; Jiangyang Zhang; Yue-Ming Li; Jarek Maciaczyk; Guido Nikkhah; Francesco Dimeco; Sara Piccirillo; Angelo L Vescovi; Charles G Eberhart
Journal:  Stem Cells       Date:  2010-01       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.